

Dated: March 2, 2022.

**Terrance Perry,**

*Chief Grants Management Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2022-04788 Filed 3-7-22; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### **Prospective Grant of an Exclusive Patent License: NCGC00413972 and Its Related Analogs Consisting of an Imidazo-Pyrazine Scaffold Core for the Treatment or Prevention of Cancers Expressing the Mannose Receptor CD206, Including Both Solid Tumors and Hematological Malignancies**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patent Applications listed in the **SUPPLEMENTARY INFORMATION** section of this notice to Macala Bio, Inc. located in 1000 NW Wall Street, Suite 220, Bend, OR 97703.

**DATES:** Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before March 23, 2022 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Eric Cheng, Ph.D., Licensing and Patenting Manager at (240)-276-5530 or [eric.cheng2@nih.gov](mailto:eric.cheng2@nih.gov).

#### **SUPPLEMENTARY INFORMATION:**

##### **Intellectual Property**

United States Provisional Patent Application No. 62/950,488, filed 19 December 2019 and entitled "CD206 Modulators Their Use And Methods For Preparation" [HHS Reference No. E-105-2019/0-US-01];

PCT Patent Application PCT/US2020/065238, filed 16 December 2020 and entitled "CD206 Modulators Their Use And Methods For Preparation" [HHS Reference No. E-105-2019-0-PCT-02].

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide and the field of use may be limited to: NCGC00413972 and its related analogs consisting of an imidazo-pyrazine scaffold core for the treatment or prevention of cancers expressing the mannose receptor CD206, including both solid tumors and hematological malignancies.

This technology discloses immunotherapy drugs, and to compounds that modulate CD206 as well as their use and methods for preparation.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: March 2, 2022.

**Richard U. Rodriguez,**

*Associate Director, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2022-04829 Filed 3-7-22; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### **Submission for OMB Review; 30-Day Comment Request Generic Clearance for National Cancer Institute (NCI) NCI Resources, Software and Data Sharing Forms (National Cancer Institute)**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** In compliance with the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has

submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.

**DATES:** Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication.

**ADDRESSES:** Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to [www.reginfo.gov/public/do/PRAMain](http://www.reginfo.gov/public/do/PRAMain). Find this particular information collection by selecting "Currently under 30-day Review—Open for Public Comments" or by using the search function.

**FOR FURTHER INFORMATION CONTACT:** To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Diane Kreinbrink, Office of Management Policy and Compliance, National Cancer Institute, 9609 Medical Center Drive, Rockville, Maryland, 20808 or call non-toll-free number (240) 276-7283 or email your request, including your address to: [diane.kreinbrink@nih.gov](mailto:diane.kreinbrink@nih.gov). Formal requests for additional plans and instruments must be requested in writing.

**SUPPLEMENTARY INFORMATION:** This proposed information collection was previously published in the **Federal Register** on December 20, 2021 (Vol. 86 FR 71901) and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Cancer Institute (NCI), National Institutes of Health (NIH), may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid Office of Management and Budget (OMB) control number.

In compliance with Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, NIH has submitted to OMB a request for review and approval of the information collection listed below.

*Proposed Collection:* Generic Clearance for NCI Resources, Software and Data Sharing Forms, 0925—NEW, Expiration Date xx/xx/xxxx, NCI, NIH. *Need and Use of Information Collection:*

In preparation for dissemination and sharing of data sets, forms requesting or applying for access, upload, share, and store data will be needed. The purpose of data sharing

allows data generated from one research study to be used to answer questions beyond the original study. It reinforces open scientific inquiry, encourages diversity of analysis, supports studies on data collection methods and measurement, facilitates the education of new researchers, and enables the exploration of topics not envisioned by

the initial investigators. Biomedical researchers and data scientists can use the NCI cloud resources, web interface, and computational workspaces to query, submit data, analyze, and visualize data. The forms would be used to register a scientist's research data, apply for data storage, and submit a request to access and use the data. In addition to these

forms, forms related to metadata information (*i.e.*, related to the collection of the research data; how the data was collected) would be collected for some research OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden are 5,775 hours.

ESTIMATED ANNUALIZED BURDEN HOURS

Form name	Type of respondents	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hours
<b>Request Data Access/Use</b>					
Data Access Request-Submitter .....	Individuals .....	1,500	1	45/60	1,125
Institutional Certification .....	Individuals .....	1,500	1	30/60	750
<b>Data Submission/Storage</b>					
Data Submission/Storage Request .....	Individuals .....	1,500	1	30/60	750
Institutional Certification .....	Individuals .....	1,500	1	30/60	750
<b>Request Access to/Use NCI Resources/Software</b>					
Data Resources .....	Individuals .....	1,500	1	30/60	750
<b>Project Renewal or Project Close-Out</b>					
Project Renewal or Project Close-out form .....	Individuals .....	1,500	2	15/60	750
Institutional Certification .....	Individuals .....	1,500	2	18/60	900
Totals .....	.....	10,500	13,500	.....	5,775

Dated: March 3, 2022.

**Diane Kreinbrink,**

*Project Clearance Liaison, National Cancer Institute, National Institutes of Health.*

[FR Doc. 2022-04881 Filed 3-7-22; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HOMELAND SECURITY**

**Coast Guard**

[Docket No. USCG-2010-0164]

**National Boating Safety Advisory Committee; March 2022 Meeting**

**AGENCY:** U.S. Coast Guard, Department of Homeland Security.

**ACTION:** Notice of Federal Advisory Committee meeting.

**SUMMARY:** The National Boating Safety Advisory Committee (Committee) and its Subcommittees will meet in Annapolis, MD to discuss matters relating to recreational boating safety. The meeting will be open to the public via a virtual platform. There is also limited in-person access.

**DATES:**

*Meetings:* The National Boating Safety Advisory Committee and its

Subcommittees will meet on Monday, March 28, 2022 from 1:00 p.m. until 4:30 p.m., (Eastern Daylight Time), Tuesday, March 29, 2022 from 8 a.m. until 4:30 p.m. and on Wednesday, March 30, 2022 from 8 a.m. until 12 p.m. Please note these meetings may adjourn early if the Committee has completed its business.

*Comments and supporting documentation:* To ensure your comments are received by Committee members before the meeting, submit your written comments no later than March 21, 2022.

**ADDRESSES:** The meeting will be held at the American Boat and Yacht Council at 613 Third Street, Suite10, Annapolis, MD 21403, [www.abycinc.org](http://www.abycinc.org).

*Pre-registration information:* Pre-registration is required for in-person access to the meeting, and for any attending via teleconference. In-person attendance to the meeting will be limited to the first 49 registrants, with priority for members of the Committee and Coast Guard support staff. If you are not a member of the Committee and do not represent the Coast Guard, you must request in-person attendance by contacting the individual listed in the **FOR FURTHER INFORMATION CONTACT**

section of this notice. You will receive a response noting if you are able to attend in-person or if the in-person roster is full. Additionally, the NBSAC mailing list will receive a notification when the in-person attendance roster is full.

Attendees at the meeting will be required to follow COVID-19 safety guidelines promulgated by Centers for Disease Control and Prevention (CDC), which may include the need to wear masks and by completing *Certification of Vaccination Form OMB Control No. 3206-0277*, or providing proof of vaccination. This form can be accessed at [Certification VaccinationPRAv7.pdf](#) ([menlosecurity.com](http://menlosecurity.com)). You may be asked to show this form when entering the facility. Please maintain this form during your visit. Masks will be provided for attendees. CDC guidance on COVID protocols can be found here: <https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html>.

Teleconference lines and live virtual document sharing will be available for the full meeting of the Committee.

For information on facilities or services for individuals with disabilities or to request special assistance at the meeting, contact the individual listed in